Robbins, SJackson, RonaldFenner, FrankBeaton, SMedveczky, CRamshaw, IanRamsay, Alistair2015-12-130166-3542http://hdl.handle.net/1885/81914Improved vaccines and therapies for virulent poxvirus infection are required, particularly in the light of recent threats of bioterrorism. Cidofovir (HPMPC) is an acyclic nucleoside analog with proven efficacy against poxviruses. Here, we evaluated HPMPCKeywords: cidofovir; interleukin 4; animal model; animal tissue; cellular immunity; controlled study; drug effect; drug efficacy; drug megadose; Ectromelia virus; lethality; mortality; mouse; nonhuman; Poxvirus infection; priority journal; review; single drug dose; Cidofovir; Immune suppression; Interleukin-4; Mousepox infection200510.1016/j.antiviral.2004.12.0032015-12-11